



14th October 2016

BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	18098.94	-0.25%	+3.87%
S&P 500	2132.55	-0.31%	+4.34%
Nasdaq	5213.33	-0.49%	+4.11%
Nikkei	16856.37	+0.49%	-11.87%
Stoxx 600	335.621	-0.87%	-8.25%
CAC 40	4405.17	-1.06%	-5.00%
Oil /Gold			
Crude WTI	50.18	0.00	+34.89%
Gold (once)	1257.76	+0.47%	+18.39%
Currencies/Rates			
EUR/USD	1.10305	+0.16%	+1.54%
EUR/CHF	1.0899	-0.06%	+0.23%
German 10 years	-0.036	+282.44%	-105.65%
French 10 years	0.265	-13.10%	-73.03%
Euribor	-	+-%	+-%

Economic releases :

Date	
14th-Oct	14h30 US - Advance retail sales Sep. (0.6% E)
	14h30 US - retail sales control group
	16h00 US- Michigan Confidence Oct. (92E)
	18h00 US - Fed J. Yellen Speaks at Boston Confidence
	19h00 US - Baker Hughes rig Count

Upcoming BG events :

Date	
21st-Oct	KORIAN (BG Geneva roadshow with CFO)
28th-Oct	IMERYYS (Paris roadshow)
8th-Nov	LVMH (BG Luxembourg roadshow with IR)
14th-Nov/ 15th-Nov	4th Paris Healthcare Conference
18th-Nov	ENGIE (BG Luxembourg roadshow with IR)
24th-Nov	IMERYYS (BG London roadshow with IR)

Recent reports :

Date	
13th-Oct	TEMENOS Success breeds success
12th-Oct	BOUYGUES Do not forget construction!
11th-Oct	A INBEV Fox in the Hen House
7th-Oct	SAINT GOBAIN : Endless sluggishness is not our scenario (report released today)
7th-Oct	ALTICE Lower risk profile
7th-Oct	ALTICE Lower risk profile

List of our Reco & Fair Value : Please click here to download

EDENRED

NEUTRAL, Fair Value EUR22 (+7%)

Conference call Q3 revenue: Scalded cat fears cold water but...

Positive numbers in Q3, with all parameters outpacing the consensus. In fact, and despite negative calendar effects compared with previous quarters, Ifl growth in Q3 gathered pace with a positive contribution from all regions and all families of services. Nevertheless and despite sustained positive dynamics in Q4, management simply confirmed its FY 2016 guidance, notably EBIT between EUR350m and EUR370m compared with EUR341m in 2015. Again, caution is mainly due to currency volatility bearing in mind that group guidance takes into account a EUR35m negative currency effect, which sounds a bit excessive to us based on current forex.

FAURECIA

BUY, Fair Value EUR47 (+38%)

A poor Q3 as expected, affected by decline in Europe & unfavourable FX/scope effects

As expected, Faurecia posted poor Q3 sales yesterday after market, with group business affected by production decline in Europe and by unfavourable FX/scope effects. All targets were reiterated, yet we negatively adjusted our 2016 sales and EBIT estimates by respectively 2% and 1%. We continue to play Faurecia for its margin and EPS improvement, thanks notably to self-help measures, and not for its ability to outperform automotive production.

SOFTWARE AG

BUY, Fair Value EUR40 (+8%)

Preliminary Q3 2016 results below estimates due to late deals; FY16 guidance reiterated

This morning, Software AG pre-announced Q3 2016 results with revenues 7% below the consensus average and non-IFRS operating profit only 2% below thanks to a non-IFRS op. margin up 1.2ppt to 33.7% vs BGe 31.7% (consensus: 32%), while EUR7.3m of DBP licence sales slipped to early October. Management considers that the sales pipeline remains promising, and reiterates FY16 guidance. As Software AG reports its first quarterly miss after 6 consecutive quarters above consensus, we expect the share price to react negatively short-term.

UNILEVER

NEUTRAL, Fair Value EUR43 (+9%) UNILEVER PLC (3890p vs. 3590p)

A mixed bag

The negative share price reaction appears to be excessive. The market reacted very negatively to the slowdown in volumes and the Tesco news. But there were some positives. The rate of decline of spreads in North America slowed down over the quarter and the pricing environment is expected to become more favourable as commodity prices are now stable/slightly up. The release has a roughly neutral impact on figures. Unilever confirmed that the underlying growth rate remains around 4%, in the middle of the sales guidance for 2016 (3-5%) and in line with our estimate. It also reiterated that the EBIT margin should increase 30-40bps this year, in line with the historical performance.

In brief...

ALTICE, Increase in stake in SFR Group to 82.94% of the capital

ENGIE, Neptune O&G said to be in talks to buy company's E&P assets

LAFARGEHOLCIM, Ahead of the Capital Market Day (18 November)

TELECOM SERVICES, ARCEP awards 4G frequencies in French overseas territories.

Business Services

Edenred

Price EUR20.53

Conference call Q3 revenue: Scalded cat fears cold water but...

Fair Value EUR22 (+7%)

NEUTRAL

Bloomberg	EDEN.FP
Reuters	EDEN.PA
12-month High / Low (EUR)	21.5 / 13.9
Market Cap (EUR)	4,799
Ev (BG Estimates) (EUR)	5,664
Avg. 6m daily volume (000)	746.1
3y EPS CAGR	11.1%

	1 M	3 M	6 M	31/12/15
Absolute perf.	3.1%	3.7%	16.3%	17.7%
Travel&Leisure	-5.3%	-5.1%	-11.6%	-19.5%
DJ Stoxx 600	-0.9%	-0.1%	-2.2%	-8.3%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	1,069	1,128	1,239	1,313
% change		5.5%	9.8%	6.0%
EBITDA	388	421	485	525
EBIT	341.0	372.1	431.5	467.7
% change		9.1%	16.0%	8.4%
Net income	206.0	220.2	255.3	278.9
% change		6.9%	16.0%	9.3%

	2015	2016e	2017e	2018e
Operating margin	31.9	33.0	34.8	35.6
Net margin	16.6	19.0	20.1	20.7
ROE	-12.2	-12.2	-13.6	-14.8
ROCE	-44.8	-44.2	-46.7	-49.5
Gearing	NM	NM	NM	NM

(EUR)	2015	2016e	2017e	2018e
EPS	0.87	0.94	1.09	1.19
% change	-	8.3%	16.0%	9.3%
P/E	23.6x	21.8x	18.8x	17.2x
FCF yield (%)	6.0%	8.7%	10.4%	9.4%
Dividends (EUR)	0.84	0.89	1.04	1.13
Div yield (%)	4.1%	4.4%	5.1%	5.5%
EV/Sales	5.1x	5.0x	4.6x	4.3x
EV/EBITDA	14.0x	13.5x	11.6x	10.7x
EV/EBIT	15.9x	15.2x	13.1x	12.0x

Positive numbers in Q3, with all parameters outpacing the consensus. In fact, and despite negative calendar effects compared with previous quarters, lfl growth in Q3 gathered pace with a positive contribution from all regions and all families of services. Nevertheless and despite sustained positive dynamics in Q4, management simply confirmed its FY 2016 guidance, notably EBIT between EUR350m and EUR370m compared with EUR341m in 2015. Again, caution is mainly due to currency volatility bearing in mind that group guidance takes into account a EUR35m negative currency effect, which sounds a bit excessive to us based on current forex.

ANALYSIS

Higher Q3 lfl growth despite negative calendar effect: Stronger than anticipated lfl growth in Q3 with an acceleration vs. previous quarters despite negative calendar effect of one day vs. +2 days in Q2 and none in Q1:

- o Issue volume was up 10.2% on lfl vs. 8.5% from consensus at EUR4,833m o/w 8.2% in Employee Benefits and 17.2% in Expense Management. All in all for the first 9m, IV was up 8.9% on lfl (+7.4% in Q1, 9.3% in Q2 and 10.2% in Q3). Note that currencies impacted negatively IV of 9.1% despite positive trend of Brazilian real of 8.7% in Q3. By geography, **France** (16.5% of IV) was up 4.6% in 9m after 3.4% in Q3, **Rest of Europe** (31%) +9.2% after 7.7% in Q3, **Latam** (48.5%) +10% after 14.3% in Q3 (**Brazil** was up 4.5% after same number in Q3) and **RoW** (4%) +9.8% after 6% in Q3.
- o Revenue also grew at a sustainable pace, up 9.1% in Q3 vs. 6.4% from consensus at EUR278m. In the first 9m, lfl reached 7% on lfl (+5.2% in Q1, 6.9% in Q2 and 9.1% in Q3). Note that financial revenue was down 1.9% in 9m after -2.5% in Q3. By region, revenue growth (with IV) was sustained in all regions with **Europe** up 7.1% in 9m after 7.3% in Q3, **Latam** +8.3% after 12.5% in Q3 and **RoW** up 6.4% after 2.4% in Q3.

Nevertheless, FY guidance was simply confirmed: Management confirmed all its targets for FY 2016 i.e. organic growth in issue volume at the lower end of the historical target of 8-14% (our forecast is 8.6% after 8.9% at the end of 9m), an operating flow-through ratio of more than 50% (60.2%), lfl FFO growth of over 10% (18.6%) and an EBIT between EUR350 and EUR370m taking into account an estimated negative currency effect of EUR35m. We are confirming our EBIT of EUR372m (consensus at EUR364m), including a negative currency effect of EUR19m.

VALUATION

At the current share price, the stock is trading at 15.2x EV/EBIT 2016e and 13.1x 2017e which compares with CAGR EBIT 2015-2018 of 11%.

NEXT CATALYSTS

CMD (London) on 19th October
 FY 2016 results on 23rd February

[Click here to download](#)



Analyst :
 Bruno de La Rochebrochard
 33(0) 1 56 68 75 88
 bdelarochebrochard@bryangarnier.com

Automotive

Faurecia

Price EUR34.05

A poor Q3 as expected, affected by decline in Europe & unfavourable FX/scope effects

Fair Value EUR47 (+38%)

BUY

As expected, Faurecia posted poor Q3 sales yesterday after market, with group business affected by production decline in Europe and by unfavourable FX/scope effects. All targets were reiterated, yet we negatively adjusted our 2016 sales and EBIT estimates by respectively 2% and 1%. We continue to play Faurecia for its margin and EPS improvement, thanks notably to self-help measures, and not for its ability to outperform automotive production.

ANALYSIS

Main Q3-16 metrics: Total sales for Q3 came out at EUR4.24bn, down 1.9% YoY and up 1.6% LfL while its value added sales were almost flat at EUR3.53bn compared with last year, but up 3.7% on a LfL basis. This should be compared with +3.4% and +5% LfL sales growth posted by the group during first semester. Consensus stood at EUR4.374bn in line with our estimates (BG @ EUR4.38bn). Over this quarter, the group suffered from lower precious metal (-9%) affecting its monolith (pass-through) revenues, from negative FX effect (-1.9%) and from negative scope effect (-1.5%) following the disposal of the Foutain Inn plant.

What to retain from this publication? 1/European sales (-3% YoY and -1.9% LfL) were hit by lower output from VW and Ford (Ford Focus & Ford Fiesta). Market production fell by 2% over the quarter. The group indicated that the region should not be better in Q4 (stability of production due to one working day less and production adjustment of key customer (Daimler and Ford)). 2/Group's North American sales was almost flat organically while market production was up 2%. This underperformance was mainly due to the Chrysler 200 production cut, as well as the F-150 lower output. 3/Group's performance in Asia was impressive at +18% LfL (vs. only +3.8% in published in H1-16) yet the group indicated that it has underperformed Chinese LV production, still penalized by its exposure to PSA. Interestingly Faurecia indicated its sales to Chinese OEMs increased by 40% and now represented 14% of group's Chinese business, vs. 13% previously. On a more mid-term view, the group indicated that 4/it saw a strong order intake acceleration since 2015 (contrasting with 2013 & 2014) for which impact on sales will be visible from H2 2017. H1 2017 will be driven by JVs activity launch/ramp-up in China and Brazil. It also indicated that 5/LatAm seems to stabilize and a change of trend in Brazil should positively impact production in the next quarter. Its JV in Brazil should be close to breakeven by H1 2017 (-EUR20m FY2016e). Finally the group confirmed its 2016 guidance (total LfL sales growth of +1/+3%, operating margin of 5% minimum and minimum net cash flow of EUR300m) while indicated its 2016 group's sales will be affected by -2% on FX effect and by -1% on scope effect. It also upgraded its restructuring costs in US linked to FCA issue by EUR10m to EUR70m.

We adjust our 2016 estimates by 2%: We adjusted our 2016 estimated with more unfavourable FX and scope effect and integrated now expect the group to post LfL sales growth of 2.5% vs. +3% previously. We then adjusted our 2016 sales estimates by 2% and our 2016 EBIT estimates by less than 1%.

Conclusion: This poor third quarter is not a surprise given that we knew the group would be negatively affected by a production decline in Europe. Despite these negative adjustments to our sales estimates, we keep our FV unchanged at EUR47/share. Faurecia is not an equity story based on sales growth, but on margin and EPS improvement, thanks notably to self-help measures.

VALUATION

At current share price Faurecia is trading at 5.2x its 2017e EBITDA and at 8.8x its 2017e EPS

Buy, FV @ EUR47

NEXT CATALYSTS

02nd November – Faurecia – Breakfast with IR @ Bryan Garnier Paris

[Click here to download](#)


Bloomberg	EO FP
Reuters	EPED.PA
12-month High / Low (EUR)	37.3 / 27.2
Market Cap (EUR)	4,694
Ev (BG Estimates) (EUR)	5,502
Avg. 6m daily volume (000)	556.3
3y EPS CAGR	20.2%

	1 M	3 M	6 M	31/12/15
Absolute perf.	-3.9%	8.0%	-1.1%	-4.9%
Auto & Parts	0.3%	7.0%	-1.2%	-14.7%
DJ Stoxx 600	-0.9%	-0.1%	-2.2%	-8.3%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	18,770	18,804	19,591	20,433
% change		0.2%	4.2%	4.3%
EBITDA	1,442	1,547	1,588	1,769
EBIT	830.0	928.7	1,034	1,146
% change		11.9%	11.4%	10.9%
Net income	371.8	497.2	536.2	623.6
% change		33.7%	7.8%	16.3%

	2015	2016e	2017e	2018e
Operating margin	4.4	4.9	5.3	5.6
Net margin	2.0	2.6	2.7	3.1
ROE	14.2	23.1	15.7	16.0
ROCE	12.6	16.6	17.0	17.5
Gearing	36.2	4.2	1.5	-3.5

(EUR)	2015	2016e	2017e	2018e
EPS	2.60	3.60	3.88	4.52
% change	-	38.4%	7.8%	16.3%
P/E	13.1x	9.5x	8.8x	7.5x
FCF yield (%)	4.5%	5.3%	4.6%	7.2%
Dividends (EUR)	0.65	1.01	1.09	1.27
Div yield (%)	1.9%	3.0%	3.2%	3.7%
EV/Sales	0.4x	0.3x	0.3x	0.3x
EV/EBITDA	4.6x	3.6x	3.4x	2.9x
EV/EBIT	8.0x	5.9x	5.2x	4.5x



Analyst :
Xavier Caroen
33(0) 1.56.68.75.18
xcaroen@bryangarnier.com

Sector Team :
Pierre-Antoine Chazal

TMT

Software AG

Price EUR37.03

Preliminary Q3 2016 results below estimates due to late deals; FY16 guidance reiterated

Fair Value EUR40 (+8%)

BUY

Bloomberg	SOW GR
Reuters	SOWG.DE
12-month High / Low (EUR)	38.9 / 23.8
Market Cap (EUR)	2,925
Ev (BG Estimates) (EUR)	2,794
Avg. 6m daily volume (000)	188.0
3y EPS CAGR	4.9%

This morning, Software AG pre-announced Q3 2016 results with revenues 7% below the consensus average and non-IFRS operating profit only 2% below thanks to a non-IFRS op. margin up 1.2ppt to 33.7% vs BGe 31.7% (consensus: 32%), while EUR7.3m of DBP licence sales slipped to early October. Management considers that the sales pipeline remains promising, and reiterates FY16 guidance. As Software AG reports its first quarterly miss after 6 consecutive quarters above consensus, we expect the share price to react negatively short-term.

	1 M	3 M	6 M	31/12/15
Absolute perf.	2.6%	18.7%	8.8%	40.1%
Softw. & Comp.	-0.5%	10.7%	9.3%	5.3%
DJ Stoxx 600	-0.9%	-0.1%	-2.2%	-8.3%

ANALYSIS

Q3 2016 results below expectations due to late deal closings. Based on preliminary figures, Q3 2016 sales were down 8.1% (-7.1% lfl) to EUR198.3m, or 8% below our forecast (EUR215.3) and 7% behind the consensus (EUR212.6m), due to EUR7.3m of DBP licence sales that slipped from Q3 to the first days of October. Non-IFRS operating profit was down 4.8% to EUR66.8m or 33.7% of sales (+1.2ppt) or only 2% below our estimate (EUR68.3m or 31.7%) and the consensus (EUR68m or 32%). IFRS EBIT was down 25% to EUR50.1m (BG est.: EUR57.1m; consensus: EUR56.4m) after a EUR5.4m one-time charge related to a lawsuit in the US. Licence sales were down an est. 32% lfl to EUR46.9m or 27% below our est. (EUR64.6m) and 25% behind the consensus (EUR62.5m), while maintenance was up 4% lfl to EUR104m (BG est.: EUR104.2m; consensus: EUR102.9m). Finally, the management estimates that free cash flow was up 25-35% in Q3 2016 (up 10-13% year-to-date). Restated from the EUR7.3m that slipped, pro forma Q3 revenues would have been down 4% lfl to EUR205.5m, or 3% below consensus however due to a weak quarter for Adabas & Natural (A&N) on licence sales - probably in relation with licence revenue seasonality.

Details by division. 1). For the **Digital Business Platform (DBP) division**, Product sales were down 1.2% (est. +1% lfl) to EUR101.9m (BG est.: EUR110.8m, consensus: EUR109.9m), of which EUR37.5m (est. -8% lfl) in licences and +6% lfl on maintenance, while the business line margin was up 7.3ppt to 35.4% (BG est.: 32.7%) thanks to sales and marketing costs down 20%; 2). For the **A&N (Adabas & Natural) division**, Product sales were down 26.6% (-26% lfl) to EUR49.1m (BG est.: EUR58.2m; consensus: EUR55.5m), of which EUR9.3m (-66% lfl) in licences and +1% lfl on maintenance, while the business line margin was down 2.5ppt to 73.7% (BG est.: 71.1%); 3). For **Consulting**, sales were up 3.2% (+5% lfl) to EUR447.3m (BG est.: EUR46.3m; consensus: EUR47.2m) with a business line margin 1.4ppt to 15.5% (BG est.: 9.4%) with a gross margin up 0.7ppt to 25.8%.

FY16 guidance reiterated. For FY16, Software AG still expects DBP Product sales up 5-10% at cc, A&N Product sales down 2-6% at cc, and a non-IFRS operating margin of 30.5-31.5%. These figures are roughly in line with our forecasts, as we expect +6.3% for DBP, -1.5% for A&N, and a non-IFRS operating margin of 31.5% (consensus: 31.9%). DBP revenues year-to-date as of 11th October, up 5% lfl, are at the low-end of the guidance range, but the management in the press release talks about a promising project pipeline. On their side, A&N revenues were down 5% lfl year-to-date, or at the low-end of full-year guidance, but Q4 2015 was down 15% lfl.

YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	873.1	887.6	916.7	958.8
% change		1.7%	3.3%	4.6%
EBITDA	278	289	304	325
EBIT	209.4	237.7	258.2	280.4
% change		13.5%	8.6%	8.6%
Net income	188.0	191.7	201.5	217.0
% change		1.9%	5.1%	7.7%

	2015	2016e	2017e	2018e
Operating margin	30.2	31.0	31.5	32.4
Net margin	16.0	17.7	18.8	19.7
ROE	12.8	13.0	13.0	12.9
ROCE	17.7	18.4	19.7	21.8
Gearing	1.3	-10.9	-21.8	-31.5

(€)	2015	2016e	2017e	2018e
EPS	2.33	2.38	2.50	2.69
% change	-	1.9%	5.1%	7.7%
P/E	15.9x	15.6x	14.8x	13.8x
FCF yield (%)	5.9%	6.6%	7.0%	7.6%
Dividends (€)	0.55	0.60	0.65	0.70
Div yield (%)	1.5%	1.6%	1.8%	1.9%
EV/Sales	3.4x	3.1x	2.9x	2.6x
EV/EBITDA	10.6x	9.7x	8.7x	7.6x
EV/EBIT	11.2x	10.2x	9.1x	7.9x



VALUATION

- Software AG's shares are trading at est. 10.2x 2016 and 9.1x 2017 EV/EBIT multiples.
- Net cash position on 30th June 2016 was EUR65.8m (net gearing: -6%).

NEXT CATALYSTS

Conference call today at 10am CET / 9am BST / 10am EDT (UK: +44 20 30 59 81 28; USA: +1 631 302 65 47).

[Click here to download](#)



Analyst :
Gregory Ramirez
33(0) 1 56 68 75 91
gramirez@bryangarnier.com

Sector Team :
Richard-Maxime Beaudoux
Thomas Coudry
Dorian Terral

Food & Beverages

Unilever

Price EUR39.47

A mixed bag

Fair Value EUR43 (+9%) UNILEVER PLC (3890p vs. 3590p)

NEUTRAL

Bloomberg	UNA NA
Reuters	UNC.AS
12-month High / Low (EUR)	42.9 / 36.7
Market Cap (EURm)	112,658
Ev (BG Estimates) (EURm)	100,856
Avg. 6m daily volume (000)	3,893
3y EPS CAGR	6.3%

	1 M	3 M	6 M	31/12/15
Absolute perf.	-2.5%	-5.6%	-2.3%	-1.6%
Food & Bev.	-1.1%	-3.4%	0.6%	-3.0%
DJ Stoxx 600	-0.9%	-0.1%	-2.2%	-8.3%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	53,272	52,877	55,625	58,288
% change		-0.7%	5.2%	4.8%
EBITDA	9,235	9,340	10,092	10,863
EBIT	7,865	7,965	8,590	9,231
% change		1.3%	7.8%	7.5%
Net income	5,210	5,320	5,785	6,261
% change		2.1%	8.7%	8.2%

	2015	2016e	2017e	2018e
Operating margin	14.8	15.1	15.4	15.8
Net margin	9.8	10.1	10.4	10.7
ROE	NM	NM	NM	NM
ROCE	18.9	18.8	20.5	22.1
Gearing	NM	NM	NM	NM

(EUR)	2015	2016e	2017e	2018e
EPS	1.82	1.86	2.03	2.19
% change	-	2.1%	8.7%	8.2%
P/E	21.6x	21.2x	19.5x	18.0x
FCF yield (%)	4.3%	3.8%	4.3%	4.4%
Dividends (EUR)	1.21	1.30	1.41	1.52
Div yield (%)	3.1%	3.3%	3.6%	3.9%
EV/Sales	1.9x	1.9x	1.8x	1.8x
EV/EBITDA	11.0x	10.8x	10.1x	9.5x
EV/EBIT	12.9x	12.7x	11.9x	11.2x

The negative share price reaction appears to be excessive. The market reacted very negatively to the slowdown in volumes and the Tesco news. But there were some positives. The rate of decline of spreads in North America slowed down over the quarter and the pricing environment is expected to become more favourable as commodity prices are now stable/slightly up. The release has a roughly neutral impact on figures. Unilever confirmed that the underlying growth rate remains around 4%, in the middle of the sales guidance for 2016 (3-5%) and in line with our estimate. It also reiterated that the EBIT margin should increase 30-40bps this year, in line with the historical performance.

ANALYSIS

- Unilever reported Q3 sales of EUR13.4bn, globally stable YoY. The organic sales growth came out at +3.2%, ahead of expectations (consensus: +2.8% vs our estimate: +3.2%). Pricing was up 3.6% but volumes decreased 0.4%, slowing down vs H1 (+2.2%). This is the worst performance since Q4 2014 and is mainly due to LATAM (16% of total sales) where the volumes trend decelerated from -0.4% in H1 to -5% in Q3 as a result of lower consumer disposable income. Market volumes were down by 10% in Brazil and 7% in Argentina in the quarter. Asia/AMET/RUB (42% of total sales) also deteriorated. Volumes in Q3 increased 0.6% while they were up 4% in H1. The region was penalized by 1/ India (8% of total sales) where volumes of skin cleansing products suffered from prices that were increased to recover rising commodity costs and 2/ China, impacted by the rapid shift to e-commerce (now 10% of the group's sales vs 3% two years ago) which is causing destocking and intense price competition from local players (not sustainable according to the group). Finally, in Europe (25% of total sales), volumes were stable in Q3, decelerating vs H1 (+1.8%) because of the UK where tea and laundry suffered from tough price competition and spreads continued to drop.
- Market has been greatly disappointed by the slowdown in volumes. It also probably reacted negatively to the Tesco news. Yesterday morning the press reported that Unilever's products including Marmite, Ben & Jerry's and Pot Noodles have been disappearing from Tesco shelves amid a dispute between the supermarket and the company. The row developed when Unilever, which faces higher costs after the fall in value of the pound, attempted to pass them on in higher wholesale prices. Yesterday evening, Unilever said that this disagreement has ended.
- The negative share price reaction appears to be excessive. The rate of decline of spreads in North America slowed down over the quarter. Additional good news is that the pricing environment is expected to become more favourable as commodities prices are now stable/slightly up. Yesterday's release was broadly neutral for figures. Unilever confirmed that the underlying growth rate remains around 4%, in the middle of the sales guidance for 2016 (3-5%) and in line with our estimate. The Q4 sales trend should remain weak because of tough market conditions in LATAM and destocking in China. The group has also reiterated that the EBIT margin should increase 30-40bps this year, in line with the historical performance. Our estimate now calls for +30bps to 15.1% (15.2% previously). It expects FX to impact sales by >5% and EPS by 3-4%.

VALUATION

- Our DCF points to a Fair Value of EUR43 for Unilver NV and 3890p for Unilever PLC (3590p previously).

NEXT CATALYSTS

- Q3 2016 sales: Danone on October 18th and Nestlé on October 20th

[Click here to download](#)



Analyst :
 Virginie Roumage
 33(0) 1.56.68.75.22
 vroumage@bryangarnier.com

Sector Team :
 Nikolaas Faes
 Loïc Morvan
 Antoine Parison
 Cédric Rossi

TMT

Altice

Price EUR15.96

Increase in stake in SFR Group to 82.94% of the capital**Fair Value EUR19 (+19%)****BUY**

Bloomberg	ATC.NA
Reuters	ATCA.AS
12-month High / Low (EUR)	19.9 / 10.0
Market Cap (EURm)	17,459
Avg. 6m daily volume (000)	1,497

	1 M	3 M	6 M	31/12/15
Absolute perf.	3.8%	19.0%	13.6%	20.4%
Telecom	-3.2%	-6.6%	-12.4%	-18.8%
DJ Stoxx 600	-0.9%	-0.1%	-2.2%	-8.3%

	2015	2016e	2017e	2018e
P/E	NS	NS	32.8x	12.3x
Div yield (%)	NM	NM	NM	NM

ANALYSIS

- Altice announced this morning it has **increased its stake in SFR Group from 77.75% to 82.94%**. It has acquired SFR shares in **private off-market transactions**. In consideration for these acquisitions, Altice NV will deliver to the sellers common A shares which it held previously as **treasury shares**, reflecting an exchange ratio of **8 Altice common shares A for 5 SFR Group shares**.
- After failing to launch their exchange offer on SFR due to a no go from the AMF, Altice is buying shares off market under the **same scheme and parity** as in the planned initial offer. As of yesterday evening's closing stock price, the offer would represent a **12% premium on SFR**.
- We believe this type of move could fuel speculation on SFR. Nevertheless, as Altice gains more and more control over SFR, we still **favour being a shareholder of Altice rather than SFR**, for operational and financial concerns. In particular, we believe the remuneration agreement which could be put in place between Altice and SFR could be **detrimental** to the interests of SFR shareholders.

VALUATION

- We stick to our Fair value of EUR19 for Altice, with a Buy recommendation.

NEXT CATALYSTS

- Q3 results on 10th November.

[Click here to download](#)Thomas Coudry, tcoudry@bryangarnier.com

Utilities

ENGIE

Price EUR12.92

Neptune O&G said to be in talks to buy company's E&P assets

Fair Value EUR16.5 (+28%)

BUY

Bloomberg	ENGI.FP
Reuters	ENGIE.PA
12-month High / Low (EUR)	16.6 / 12.9
Market Cap (EURm)	31,452
Avg. 6m daily volume (000)	5 413

ANALYSIS

According to Bloomberg, Neptune Oil & Gas Ltd, the energy acquisition company backed by Carlyle Group and CVC Partners, is in **talks to buy Engie's E&P business**. The investment vehicle is said to have made an **initial offer** for the company's assets that span the UK, Norway, Algeria, Egypt, Germany and Asia. Neptune is planning about USD5bn of investments by taking advantage of a large number of assets sales particularly by industry giants.

No final decision has been made yet and Neptune is not close to an agreement at the moment, according to people familiar with the matter. This is however **positive** for Engie which **maintains the positive momentum from disposal of non-strategic assets**. On top of current talks over the E&P business, Engie is also said to be in negotiations regarding potential disposals of **1/** its Polaniec thermal power plants in Poland; **2/** its port project in northern Chile; **and 3/** its 2nd power plant project in Mejillones (375MW) in Chile called IEM2.

Higher oil prices, on the back of the potential OPEC agreement, **improved prospects** for the sale of these E&P assets. Engie is however still hammering home that **it would hold out for the right price** in order to maximize the valuation of these assets.

As a reminder, we valued the E&P business at c. **EUR5.4bn** in our SOTP. As Engie owns 70% of the business, this would represent a c. **EUR3.8bn** cash-in for the company i.e. about 25% of the company's disposals target by 2020 (**EUR15bn**).

VALUATION

At current share price, Engie is trading at **6.4x** its 2016e EV/EBITDA multiple

Buy, FV @ EUR16.5

NEXT CATALYSTS

10th November: Q3-16 results

Pierre-Antoine Chazal, pachazal@bryangarnier.com

Construction & Building Materials

LafargeHolcim

Price CHF49.70

Ahead of the Capital Market Day (18 November)

Fair Value CHF60 (+21%)

BUY-Top Picks

ANALYSIS

CEO Eric Oslen gave an interview in the French Daily *Les Echos*. Numerous subjects have been raised. In particular, the group wants to optimise its logistic networks in the Emerging Markets, which represents more than 60% of LHN EBITDA, according to our calculations. This focus is explained by the distribution structure of EM, where cement players are mostly selling cement in bags, while in mature countries it is more sold in bulk and directly to final customers, i.e. contractors. Hence the importance of wholesalers in EM, as well as brands. But this distribution system has a cost, and Eric Oslen explains that he wants to better control the distribution in order to reintegrate the margin lost through wholesalers. We understand the group is likely to set up some franchise networks for instance and develop digital distribution. More on 18 November.

As was suggested by the Chairman Beat Hess last September in the Swiss press, we understand the name of the company might change. In our view, this could be a way to help to get over the recent difficulties of the company and perhaps strengthen the brand, a key issue in EM.

Finally, Mr Oslen said details regarding the new cost cutting plan recently announced, as well as the strategy to manage energy prices increase, will be disclosed on the 18 Nov. Market Day. While higher energy costs will impact 2017 figures, a bit of inflation might be welcome to increase prices.

VALUATION

CHF60 FV derived from the application of historical multiples to of 2018 estimates, discounted back

NEXT CATALYSTS

Q3 results on 4 November. Capital Market Day on 18 November 2016.

[Click here to download](#)

Bloomberg	LHN VX
Reuters	LHN.VX
12-month High / Low (CHF)	57.7 / 34.1
Market Cap (CHFm)	30,163
Avg. 6m daily volume (000)	1,717

	1 M	3 M	6 M	31/12/15
Absolute perf.	0.0%	14.1%	2.5%	-1.2%
Cons & Mat	0.4%	5.5%	3.2%	2.8%
DJ Stoxx 600	-0.9%	-0.1%	-2.2%	-8.3%

	2015	2016e	2017e	2018e
P/E	38.2x	21.4x	15.0x	10.9x
Div yield (%)	3.0%	3.3%	3.6%	3.9%

Eric Lemarié, elemarie@bryangarnier.com

Sector View

Telecom services

	1 M	3 M	6 M	31/12/15
Telecom	-3.2%	-6.6%	-12.4%	-18.8%
DJ Stoxx 600	-0.9%	-0.1%	-2.2%	-8.3%

*Stoxx Sector Indices

Companies covered

ALTICE	BUY	EUR19
BOUYGUES	BUY	EUR35
ILIAD	BUY	EUR212
NUMERICABLE SFR	NEUTRAL	EUR29,7
ORANGE	BUY	EUR17,1

ARCEP awards 4G frequencies in French overseas territories.

Arcep has selected successful candidates for new frequencies in overseas territories. As a result, **Free mobile will be a new entrant in Guadeloupe/Martinique, Barthélemy/St Martin and French Guiana, bringing new strong competition to Orange in particular.**

ANALYSIS

- Arcep announced yesterday that it has selected the **successful candidates for new frequencies in overseas territories**. Orange has been awarded frequencies for all regions (Guadeloupe/Martinique, Barthélemy/St Martin, French Guiana, La Reunion and Mayotte), where the group is already present. SFR was awarded frequencies in La Reunion and Mayotte, where the group is also already present. Free was awarded frequencies for all regions. Licenses are awarded for free.
- As a result of the allocation process, **Free mobile will be a new entrant** in Guadeloupe, Martinique, Barthélemy, St Martin, French Guiana. Free is already present in La Reunion and Mayotte through Telco OI (JV with Axian). As already announced, Free plans to invest **EUR100m** in this project. The group announced it plans to “put **an end to discriminatory tariffs** that exist today between overseas and the mainland, for which there is no justification”.
- Free mobile's entry into the market is clearly a **threat to existing players such as Orange**, although the global impact on the group should **not be material**.

VALUATION

- We stick to our fair values and recommendations for all companies we cover on the sector.

NEXT CATALYSTS

- Q3 results: Orange on 25th October, Altice/SFR on 10th November, Iliad in mid November.

Thomas Coudry, tcoudry@bryangarnier.com

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 57.4%

NEUTRAL ratings 31%

SELL ratings 11.6%

Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/Infrastructures/Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Automotive & Parts		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle Prudential et de Résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11



BRYAN, GARNIER & CO

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....